DP-b99 in the Treatment of Acute High-risk Pancreatitis

Status Terminated

Clinical Trial Summary

Inflammation of the pancreas often leads to severe damage not only to the pancreas but also to other organs in the abdomen as well as to complications in organs further away like the lung and the kidney. This trial will examine if DP-b99, given to patients with non-severe inflammation of the pancreas, can mitigate the development of processes that can lead to serious complications of this disease.

Clinical Trial Description

The study will be a randomised, double blind, placebo-controlled, multi-centre, multi-national, parallel-arm study comparing a placebo group to a DP-b99 group treated intravenously with 1.0 mg/kg twice daily for 2 consecutive days.

The study will enrol 30 patients at high risk of developing severe pancreatitis, as assessed by the Bedside Index for Severity in Acute Pancreatitis (BISAP) score of 3 or more at study entry.

The primary study endpoint is the effect of DP-b99 on systemic inflammation in acute pancreatitis as reflected by C-reactive protein (CRP) plasma levels. The secondary endpoints are the safety of DP-b99 in this population of patients (through routine safety laboratory tests, physical examination and vital signs monitoring, ECG and adverse event reporting), DP-b99's effects on other plasma inflammatory markers (interleukin-6, matrix metalloproteinase 9, tumor necrosis factor alpha) as well as its effects on the clinical course of pancreatitis (based on changes in the Systemic Inflammatory Response Syndrome (SIRS) and Acute Physiology And Chronic Health Evaluation II (APACHE II) scores, and on contrast material-enhanced abdominal Computerised Tomography (CT), versus placebo.

Clinical trial material administration will begin within 48 hours of acute pancreatitis symptoms onset. Subjects will be randomised at a ratio of 1:1 to receive either DP b99 or placebo. The serum levels of DP-b99 at the end of each 2-hour infusion will also be monitored.

The study duration per individual subject will be 14 days, consisting of a screening evaluation followed by a 48-hour double blind treatment period, which will be part of an in-hospital observation period of at least 6 days, and a follow-up final visit on Day 14. ;

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Pancreatitis

Clinical Trial Details

NCT number	NCT02025049
Study type	Interventional
Source	D-Pharm Ltd.
Contact
Status	Terminated
Phase	Phase 2
Start date	December 2013
Completion date	May 2015

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03609944` - SpHincterotomy for Acute Recurrent Pancreatitis	N/A
Not yet recruiting	`NCT04652271` - International Pancreatic Surgery Outcomes Study - PancreasGroup.Org
Completed	`NCT01441492` - Pancreas Resection With and Without Drains	N/A
Recruiting	`NCT02196935` - Los Angeles Prospective GI Biliary and EUS Series
Completed	`NCT01476995` - Prognostic Indicators as Provided by the EPIC ClearView	N/A
Completed	`NCT01545167` - The North American Pancreatitis Study	N/A
Completed	`NCT04168801` - Early Oral Refeeding in Mild Acute Pancreatitis	N/A
Recruiting	`NCT03334708` - A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma
Completed	`NCT01824186` - Trial Comparing Pain in Single-incision Laparoscopic Cholecystectomy Versus Conventional Laparoscopic Cholecystectomy	N/A
Terminated	`NCT00428025` - Diclofenac for the Prevention of Post-ERCP Pancreatitis in Higher Risk Patients	Phase 4
Completed	`NCT00639314` - Trial on the Evaluation of Pylorus-ring in Pancreaticoduodenectomy	N/A
Recruiting	`NCT00160836` - Biliary Tissue Sampling Using a Cytology Brush or the GIUM Catheter	Phase 1
Completed	`NCT00121901` - Does Glyceryl Nitrate Prevent Post-Endoscopic Retrograde Cholangiopancreaticography (ERCP) Pancreatitis?	Phase 3
Completed	`NCT00999232` - Assess the Effect of Erythromycin on the Rate of Success in Placement of a Self-propelled Feeding Tube	Phase 4
Terminated	`NCT00419549` - Efficacy Study of Glyceryl-Trinitrate Patch and Parecoxib (Valdecoxib) for the Prevention of Pancreatitis After Endoscopic Retrograde Cholangiopancreatography (ERCP)	Phase 2/Phase 3
Active, not recruiting	`NCT05095831` - EUS Shear Wave for Solid Pancreatic Lesions.
Completed	`NCT03601325` - Acute Pancreatitis: Study of Possible Etiologies and Risk Factors Affecting Outcome
Not yet recruiting	`NCT06133023` - WONDER-02 Trial: Plastic Stent vs. Lumen-apposing Metal Stent for Pancreatic Pseudocysts	N/A
Withdrawn	`NCT02465138` - A Randomized Controlled Trial of IV Ketorolac to Prevent Post-ERCP Pancreatitis	Phase 4
Recruiting	`NCT02971475` - ESWL Versus ESWL and Endoscopic Treatment	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.